These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22552994)

  • 1. Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics.
    Singh S; Kumar N; Loftus EV; Kane SV
    Inflamm Bowel Dis; 2013; 19(4):864-72. PubMed ID: 22552994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurology of inflammatory bowel disease.
    Ferro JM; Oliveira Santos M
    J Neurol Sci; 2021 May; 424():117426. PubMed ID: 33810878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurologic manifestations of inflammatory bowel diseases.
    Ferro JM; Oliveira SN; Correia L
    Handb Clin Neurol; 2014; 120():595-605. PubMed ID: 24365340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurological disorders and inflammatory bowel diseases.
    Casella G; Tontini GE; Bassotti G; Pastorelli L; Villanacci V; Spina L; Baldini V; Vecchi M
    World J Gastroenterol; 2014 Jul; 20(27):8764-82. PubMed ID: 25083051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory bowel disease: an increased risk factor for neurologic complications.
    Morís G
    World J Gastroenterol; 2014 Feb; 20(5):1228-37. PubMed ID: 24574797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics for extraintestinal manifestations of IBD.
    Vavricka SR; Scharl M; Gubler M; Rogler G
    Curr Drug Targets; 2014; 15(11):1064-73. PubMed ID: 25198785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral neuropathy: an underreported neurologic manifestation of inflammatory bowel disease.
    García-Cabo C; Morís G
    Eur J Intern Med; 2015 Sep; 26(7):468-75. PubMed ID: 26211733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
    Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
    Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease.
    Coffin CS; Fraser HF; Panaccione R; Ghosh S
    Inflamm Bowel Dis; 2011 Jan; 17(1):479-84. PubMed ID: 20848520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neurological complications during treatment of the tumor necrosis alpha inhibitors].
    Piusińska-Macoch R
    Pol Merkur Lekarski; 2013 May; 34(203):293-7. PubMed ID: 23894783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.
    Barrie A; Regueiro M
    Inflamm Bowel Dis; 2007 Nov; 13(11):1424-9. PubMed ID: 17567879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of infections with biological agents.
    Kopylov U; Afif W
    Gastroenterol Clin North Am; 2014 Sep; 43(3):509-24. PubMed ID: 25110256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Miscellaneous adverse events with biologic agents (excludes infection and malignancy).
    Feuerstein JD; Cheifetz AS
    Gastroenterol Clin North Am; 2014 Sep; 43(3):543-63. PubMed ID: 25110258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.
    Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L
    J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orbital and optic nerve complications of inflammatory bowel disease.
    Katsanos A; Asproudis I; Katsanos KH; Dastiridou AI; Aspiotis M; Tsianos EV
    J Crohns Colitis; 2013 Oct; 7(9):683-93. PubMed ID: 23083697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of infections associated with biological treatment in inflammatory bowel disease.
    Andersen NN; Jess T
    World J Gastroenterol; 2014 Nov; 20(43):16014-9. PubMed ID: 25473153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient awareness of extraintestinal manifestations of inflammatory bowel disease.
    Huang V; Mishra R; Thanabalan R; Nguyen GC
    J Crohns Colitis; 2013 Sep; 7(8):e318-24. PubMed ID: 23265763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment.
    Wauters L; Billiet T; Papamichael K; Ballet V; Joniau S; Verschueren P; Silversmit G; Van Assche G; Vermeire S; Ferrante M
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):84-90. PubMed ID: 27603297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment.
    Di Sabatino A; Santilli F; Guerci M; Simeone P; Ardizzone S; Massari A; Giuffrida P; Tripaldi R; Malara A; Liani R; Gurini E; Aronico N; Balduini A; Corazza GR; Davì G
    Thromb Haemost; 2016 Aug; 116(3):486-95. PubMed ID: 27305860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.